Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.
Winthrop KL, Korman N, Abramovits W, Rottinghaus ST, Tan H, Gardner A, Mukwaya G, Kaur M, Valdez H. Winthrop KL, et al. Among authors: valdez h. J Am Acad Dermatol. 2018 Jun;78(6):1149-1155.e1. doi: 10.1016/j.jaad.2017.09.076. Epub 2018 Mar 2. J Am Acad Dermatol. 2018. PMID: 29080806
Herpes zoster in psoriasis patients treated with tofacitinib.
Winthrop KL, Lebwohl M, Cohen AD, Weinberg JM, Tyring SK, Rottinghaus ST, Gupta P, Ito K, Tan H, Kaur M, Egeberg A, Mallbris L, Valdez H. Winthrop KL, et al. Among authors: valdez h. J Am Acad Dermatol. 2017 Aug;77(2):302-309. doi: 10.1016/j.jaad.2017.03.023. J Am Acad Dermatol. 2017. PMID: 28711084
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J, Clark JD, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Wang CQ, Tan H, Wolk R, Rottinghaus ST, Whitley MZ, Valdez H, von Schack D, O'Neil SP, Reddy PS, Tatulych S; A3921147 Study Investigators. Krueger J, et al. Among authors: valdez h. J Allergy Clin Immunol. 2016 Apr;137(4):1079-1090. doi: 10.1016/j.jaci.2015.12.1318. J Allergy Clin Immunol. 2016. PMID: 27059729 Free article. Clinical Trial.
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C. Feldman SR, et al. Among authors: valdez h. J Am Acad Dermatol. 2016 Dec;75(6):1162-1170.e3. doi: 10.1016/j.jaad.2016.07.040. Epub 2016 Sep 28. J Am Acad Dermatol. 2016. PMID: 27692733 Clinical Trial.
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R. Strober BE, et al. Among authors: valdez h. Br J Dermatol. 2019 Jan;180(1):67-75. doi: 10.1111/bjd.17149. Epub 2018 Oct 10. Br J Dermatol. 2019. PMID: 30188571 Free PMC article.
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, Hirose T, Nduaka CI, Wang L, Mendelsohn AM, Fan H, Chen C, Bananis E. Winthrop KL, et al. Among authors: valdez h. Arthritis Rheumatol. 2017 Oct;69(10):1960-1968. doi: 10.1002/art.40189. Epub 2017 Sep 6. Arthritis Rheumatol. 2017. PMID: 28845604 Free PMC article.
213 results